Stifel on ALX Oncology (ALXO): 'our Hold thesis is based on the lack of development strategy clarity in these opportunities'
Tweet Send to a Friend
Stifel analyst Bradley Canino reiterated a Hold rating and $14.00 price target on ALX Oncology (NASDAQ: ALXO).The analyst comments "New ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
